Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada

Rheumatoid arthritis (RA) is a chronic inflammatory disorder leading to disability and reduced quality of life. Effective treatment with biologic DMARDs poses a significant economic burden. The Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Subjects with Background Methotrexate (AMPLE)...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Rheumatol Int
Hlavní autoři: Weijers, Laure, Baerwald, Christoph, Mennini, Francesco S., Rodríguez-Heredia, José M., Bergman, Martin J., Choquette, Denis, Herrmann, Kirsten H., Attinà, Giulia, Nappi, Carmela, Merino, Silvia Jimenez, Patel, Chad, Mtibaa, Mondher, Foo, Jason
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2017
Témata:
Public Health
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5486786/
https://ncbi.nlm.nih.gov/pubmed/28560470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00296-017-3739-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky